CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression

Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation

(2017) John K. Simmons et al.   MOLECULAR CANCER THERAPEUTICS

U1 Adaptors Suppress the KRAS-MYC Oncogenic Axis in Human Pancreatic Cancer Xenografts

(2017) Ashley T. Tsang et al.   MOLECULAR CANCER THERAPEUTICS

Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner

(2017) Vivek Kumar Mishra et al.   NUCLEIC ACIDS RESEARCH

HDAC8 Catalyzes the Hydrolysis of Long Chain Fatty Acyl Lysine

(2016) Pornpun Aramsangtienchai et al.   ACS Chemical Biology

Cellular and molecular aspects of pancreatic cancer

(2016) A. Gharibi et al.   ACTA HISTOCHEMICA

HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma

(2016) Yanxin Pei et al.   CANCER CELL

c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells

(2016) Eun-Ryeong Hahm et al.   CELL CYCLE

c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors

(2016) Hongyan Liu et al.   CLINICAL CANCER RESEARCH

c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

(2016) Angela Nebbioso et al.   CLINICAL CANCER RESEARCH

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers

(2016) Kaiming Sun et al.   MOLECULAR CANCER THERAPEUTICS

Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells

(2016) Natalie Grinshtein et al.   Oncotarget

Small-molecule inhibitors of the Myc oncoprotein

(2015) Steven Fletcher et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration

(2015) Ana Carolina dos Santos Ferreira et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Current status and progress of pancreatic cancer in China

(2015) Quan-Jun Lin   WORLD JOURNAL OF GASTROENTEROLOGY

Pancreatic Adenocarcinoma

(2015) David P. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncogenic KRAS signalling in pancreatic cancer

(2014) S Eser et al.   BRITISH JOURNAL OF CANCER

Therapeutic Strategies to Inhibit MYC

(2014) M. R. McKeown et al.   Cold Spring Harbor Perspectives in Medicine

MYC Activation Is a Hallmark of Cancer Initiation and Maintenance

(2014) M. Gabay et al.   Cold Spring Harbor Perspectives in Medicine

c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma

(2013) Lei Wang et al.   HEPATOLOGY

Antagonism between FOXO and MYC Regulates Cellular Powerhouse

(2013) Barrie Peck et al.   Frontiers in Oncology

MYC on the Path to Cancer

(2012) Chi V. Dang   CELL

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling

(2012) C. Qian et al.   CLINICAL CANCER RESEARCH

Current concepts and novel targets in advanced pancreatic cancer

(2012) Patrick Michl et al.   GUT

Phthalates induce proliferation and invasiveness of estrogen receptor-negative breast cancer through the AhR/HDAC6/c-Myc signaling pathway

(2011) Tsung-Hua Hsieh et al.   FASEB JOURNAL

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE